04/03/2026
The Food and Drug Administration is holding firm that not enough evidence has been gathered to support an approval filing for a closely watched genetic medicine targeting Huntington’s disease, a position that further rattled the treatment’s developer and its shareholders.
Agency staff "strongly recommended" a sham surgery-controlled trial be conducted before an approval filing, a stance one analyst called a "worst case scenario" for UniQure.